Go to Page # Page of 13

Safety Evaluation of 2

 Maja Janas PhD
  7th-Dec-2018
Description: This presentation provides information about the Safety Evaluation's Important factors include the ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of product candidates.
Views: 1273
Domain: Medical
Category: Biotech/Pharma
Space is limited, so register today!
Contents:
Safety Evaluation of 2'-Deoxy-2'-Fluoro-Modified
Nucleotides in GalNAc-siRNA Conjugates
Maja Janas, PhD, DABT
Principal Scientist, Early Development
14th Annual Meeting of the OTS
October 3rd, 2018
1

CONFIDENTIAL

© 2018 Alnylam Pharmaceuticals, Inc.

Alnylam Forward Looking Statements
This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities ... See more

Recent Presentations

Plenary Session: Research on Dementia

Plenary session: Follow up analysis suggested that the probable amnestic storage group had the highest risk of conversion to dementia. Having 8.5 times more risk to convert to deme

...
14 December, 2018
...
13 December, 2018
I-Com
12 December, 2018